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A patient with a history of breast cancer
and multiple bone lesions: a case report
Marie-Angela Schnyder1*, Paul Stolzmann2, Gerhard Frank Huber3 and Christoph Schmid1
Abstract
Background: Long-term severe hyperparathyroidism leads to thinning of cortical bone and cystic bone defects
referred to as osteitis fibrosa cystica. Cysts filled with hemosiderin deposits may appear colored as “brown tumors.”
Osteitis fibrosa cystica and brown tumors are occasionally visualized as multiple, potentially corticalis-disrupting
bone lesions mimicking metastases by bone scintigraphy or 18F-fluorodeoxyglucose positron emission tomography.
Case presentation: We report a case of a 72-year-old white woman who presented with malaise, weight loss, and
hypercalcemia. She had a history of breast cancer 7 years before. The practitioner, suspecting bone metastases,
initiated bone scintigraphy, which showed multiple bone lesions, and referred her to our hospital for further
investigations. Laboratory investigations confirmed hypercalcemia but revealed a constellation of primary
hyperparathyroidism and not hypercalcemia of malignancy; in the latter condition, a suppressed rather than an
increased value of parathyroid hormone would have been expected. A parathyroid adenoma was found and
surgically removed. The patient’s postoperative course showed a hungry bone syndrome, and brown tumors were
suspected. With the background of a previous breast cancer and lytic, partly corticalis-disrupting bone lesions, there
was a great concern not to miss a concomitant malignant disease. Biopsies were not diagnostic for either
malignancy or brown tumor. Six months after the patient’s neck surgery, imaging showed healing of the bone
lesions, and bone metastases could be excluded.
Conclusions: This case shows essential differential diagnosis in a patient with hypercalcemia and multiple bone
lesions. Whenever multiple, fluorodeoxyglucose-avid bone lesions are found, malignancy and metabolic bone
disease should both be included in the differential diagnosis. Fluorodeoxyglucose-avid and corticalis-disrupting lytic
lesions also occur in benign bone disease. There may be very few similar cases with heterogeneous and
widespread bone lesions reported in the literature, but we think our patient’s case is particularly remarkable for its
detailed imaging and the well-documented course.
Keywords: Hypercalcemia, Primary hyperparathyroidism, Osteitis fibrosa cystica, Brown tumors, Hungry bone
syndrome, 18F-FDG-PET, Lytic bone lesions
Background
Osteitis fibrosa cystica (OFC) is a rare skeletal complica-
tion of long-term severe hyperparathyroidism (HPT) [1].
Increased bone remodeling resulting from longer-term
excessive stimulation of osteoclasts by parathyroid hor-
mone (PTH) leads to subperiosteal resorption, thinning
of cortical bone, and occasionally cystic defects. The lat-
ter can be filled with hemosiderin, deposits visualized as
brown-colored “tumors” [2]. These focal reactive lesions
can be found in patients with primary or secondary
HPT. In developed countries, OFC and brown tumors
(BTs) became rare as a result of the wide application of
routine calcium screening and increased medical atten-
tion [3, 4]. BTs are often multiple, fluorodeoxyglucose
(FDG)-avid, potentially corticalis-disrupting bone lesions
mimicking metastases on bone scintigraphy or 18F-FDG-
positron emission tomography (PET) [2, 4–6]. Serum
calcium and PTH measurements are excellent diagnostic
tools, whereas bone biopsy may be less informative but
is occasionally performed to rule out an accompanying
malignancy [3]. Parathyroidectomy (PTX) is the
treatment of choice in severe HPT.
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Case presentation
A 72-year-old white woman was admitted to our
hospital because of newly diagnosed hypercalcemia
(albumin-corrected calcium 4.2 mmol/L; normal range
2.19–2.59 mmol/L) (Fig. 1a) and multiple bone lesions
visualized by bone scintigraphy. For 6 months, she had
experienced progressive weakness, bone pain, nausea,
and body weight loss of 4 kg. In addition, she noticed
nocturia and polydipsia. According to her husband, she
had recently become depressive and forgetful. Seven
years before, she had been treated for breast cancer. The
tumor stage was pT1c, pN0, M0, G2, R0; her estrogen
and progesterone receptor status was positive; and she
was herceptin 2 receptor-negative. At that time, a seg-
ment resection and a sentinel lymph node biopsy, as well
as radio- and chemotherapy, were carried out. No local
tumor recurrence had been detected in the last ultra-
sonographic follow-up of the breast and lymph nodes a
few months earlier. Having found hypercalcemia and an
elevated alkaline phosphatase (AP) level (233 U/L;
Fig. 1 a Parathyroid hormone (PTH), serum calcium, serum phosphate, and calciuria time course. Time 0 is defined as the day of parathyroidectomy
(PTX). The dashed lines and colors show the lower and upper limits of parathyroid hormone (15–65 ng/L) in orange, albumin-corrected serum calcium
(2.19–2.59 mmol/L) in blue, serum phosphate (0.87–1.45 mmol/L) in green, and calcium-to-creatinine molar ratio in urine (0.1–0.5) in yellow. Parathyroid
hormone, calcium, and calciuria are dramatically increased at baseline, and phosphate is low. Vitamin D3 (cholecalciferol) was started at week −1.
Calcium therapy was conducted orally (2 g/day for weeks 0–19, then reduced to 1 g/day). Calcitriol 0.5 μg/day was given from weeks 0 to 19, then
reduced to 0.25 μg/day and stopped at week 25. The capital letters and arrows indicate the time points at which imaging (Fig. 2a–d) and biopsies,
respectively, were performed. b Alkaline phosphatase (AP; total activity) and bone-specific alkaline phosphatase mass time course. The dashed lines and
colors show the lower and upper limits of alkaline phosphatase (35–104 U/L) in bright purple and bone-specific alkaline phosphatase (postmenopausal;
6–26 μg/L) in dark purple. Alkaline phosphatase was high before parathyroidectomy (reflecting high bone turnover resulting from hyperparathyroidism)
and further increased (reflecting increased bone formation [hungry bone syndrome]) after parathyroidectomy
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normal range 35–104 U/L), her practitioner directly ini-
tiated whole-body bone technetium-99m-3,3-dipho-
sphono-1,2-propanodicarboxylic acid (99mTc-DPD)
scintigraphy (Fig. 2a), which showed multiple active hits,
with the biggest lesions located in the os ilium and
acetabulum on the right-hand side; unspecific, diffuse
uptake in the calvarium; and multiple sites of focal
uptake at costochondral junctions. In the context of the
patient’s history of breast cancer, she was suspected of
having multiple bone metastases.
On examination, the patient appeared to be in an
afebrile, hemodynamically stable state, and no
neurologic deficits were noticed. Her body mass index
was 20.5 kg/m2. Laboratory studies showed hypercalce-
mia (albumin-corrected calcium 3.55 mmol/L), low
phosphate (0.56 mmol/L; normal range 0.87–1.45
mmol/L), impaired renal function (creatinine 119 μmol/
L, estimated glomerular filtration rate of 39 ml/minute),
elevated AP (189 U/L), and a grossly elevated PTH level
(1466 ng/L; normal range 15–65 ng/L) (Fig. 1a, b). 25-
OH-vitamin D was slightly decreased (14.2 μg/L, normal
>20 μg/L). Tumor marker CA15-3 was normal (26.7 kU/
L, normal <30 kU/L).
On the basis of the laboratory constellation of primary
HPT, neck surgery was considered and proposed to the
patient. We felt that this patient could benefit from
parathyroid surgery and correction of hypercalcemia,
regardless of a potential concomitant malignancy. Son-
ography and scintigraphy of the parathyroid glands were
performed, and a parathyroid adenoma (>2 cm in
Fig. 2 Radiographic imaging. Timing is indicated by arrows with capital letters in Fig. 1a. a Technetium-99m-3,3-diphosphono-1,2-propanodicarboxylic
acid scintigraphy with multiple hot lesions in the os ilium and acetabulum on the right-hand side. Note diffuse uptake in the calvarium and focally
pronounced uptake at the tip of the ribs, suggestive of hyperparathyroidism. b 18F-Fluorodeoxyglucose positron emission tomography demonstrates
multiple metabolically active bone lesions in correspondence with technetium-99m-3,3-diphosphono-1,2-propanodicarboxylic acid scan, but additional
fluorodeoxyglucose-positive lesions were detected, such as in the glenoid on the left-hand side (arrow). c On this 18F-fluoride-positron emission
tomographic scan, all lesions demonstrate fluoride uptake as proof of mineralization. Note fluoride uptake in flat bones and in costochondral junctions
(similarly to technetium-99m-3,3-diphosphono-1,2-propanodicarboxylic acid whole-body scintigraphy) thought to be indicative of
hyperparathyroidism and brown tumors. d Follow-up 18F-fluorodeoxyglucose positron emission tomography with no fluorodeoxyglucose-avid
lesions demonstrating a complete response 23 weeks after parathyroidectomy. Initial 18F-fluorodeoxyglucose positron emission tomography/computed
tomography shows an additional fluorodeoxyglucose-positive lesion in the left glenoid (e) not depicted in former technetium-99m-3,3-diphosphono-1,2-
propanodicarboxylic acid scanning. The lesion exhibits sharply demarcated borders and evidence of subperiosteal bone resorption on computed
tomography (f, arrow) thought to be pathognomonic for hyperparathyroidism. The lesion shows fluoride uptake in 18F-fluoride positron emission
tomography/computed tomography (g) and demonstrates progressive sclerosis of the central matrix in computed tomography (h, arrow) after initiation of
therapy. In 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging 23 weeks after parathyroidectomy, neither abnormal
fluorodeoxyglucose uptake nor signal abnormalities are detected in the glenoid in T1-weighted (i) and T2-weighted images (j)
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diameter) was detected at the left inferior side. Concern-
ing the possible metastatic bone disease, 18F-FDG-PET/
computed tomography (CT) was carried out (Fig. 2b).
This examination provided evidence of multiple meta-
bolically active, predominantly lytic bone lesions in the
pelvis and at the sternum as well as a corticalis-
disrupting lesion in the glenoid on the left-hand side
(Fig. 2e, f ).
The patient received intravenous continuous hydration
(isotonic saline) and oral vitamin D3 (cholecalciferol
2000 U/day), and she consented to the proposed para-
thyroid surgery, which was carried out 1 week later.
Following removal of the enlarged parathyroid gland
(suspected to be the single source of excessive PTH;
weighing 4.5 g), the patient’s intraoperative PTH level
decreased to 22.6 ng/L (Fig. 1a), indicating removal of
the culprit lesion. As expected, the lesion was posterior
to the left lower thyroid pole and completely removed.
In the postoperative course, no local (neck) complica-
tions were noticed.
After surgery, there was a progressive fall in serum
calcium (total calcium down to a nadir of 1.96 mmol/L
on day 5; albumin-corrected as shown in Fig. 1a),
whereas phosphate remained low (0.52 mmol/L on the
fifth postoperative day, returning to within the normal
range 7 weeks later), and AP activity further increased
up to 395 U/L 2 weeks after PTX (Fig. 1b). This increase
could be attributed to an increase in the bone isoenzyme
because bone-specific AP mass (up to 121 μg/L, normal
postmenopausal range 6–26 μg/L) peaked at around the
same time and came back to within the normal range by
week 12 after PTX. PTH increased during the initial
postoperative course (with low postoperative calcium) to
300 ng/L, ruling out hypoparathyroidism, and fasting
urinary spot calcium excretion decreased to a level
below the detection limit (Fig. 1a) and remained low
(urinary calcium/creatinine molar ratio <0.1) until 10
weeks after surgery. This constellation suggested hungry
bone syndrome (HBS), a common consequence follow-
ing successful parathyroid surgery in patients with OFC,
and we considered this postoperative course compatible
with the bone lesions [1]. We started therapy with oral
calcium (2 g/day) and calcitriol (0.5 μg/day), we contin-
ued treating the patient with vitamin D3 (2000 U/day,
long-term). Owing to initial diagnostic uncertainty,
signals sent by some physicians to the patient, and her
fear of recurring malignancy, the largest lesion in the
area of the pelvis was biopsied with CT guidance in an
outpatient setting (3 weeks after PTX) (Fig. 1a). No
malignant cells could be found, but the material turned
out to be insufficient for pathological diagnosis by histo-
logical and immunohistochemical investigations. With
the aim of gaining more information in the setting of an
elevated AP (reflecting elevated bone turnover), we
performed 18F-fluoride-PET (Fig. 2c, g, h) 7 weeks after
PTX. In this investigation, all the lesions showed
increased fluoride uptake and progressive sclerosis of
some lesions reflecting bone mineralization. Additional
open biopsies were performed 9 weeks after PTX
(Fig. 1a). Tissue samples of the right patella and of the
right os ilium (the most reachable lesions) were
obtained; again, no malignant cells were found.
We regularly saw the patient in our consultation, and
laboratory controls showed that the serum calcium
could be kept in the normal range over weeks (Fig. 1a).
The therapy with calcium and calcitriol was adapted
continuously. Six months after PTX, the patient
presented with a joint effusion of the left knee. The
rheumatologists conducted a joint puncture, and aspir-
ation material showed calcium pyrophosphate crystals.
Twenty-three weeks after PTX and bone lesions of
unknown etiology and significance, we conducted
further follow-up imaging by 18F-FDG-PET/magnetic
resonance imaging (MRI) (Fig. 2d, i, j) to prove BTs and
again rule out malignancy. The bone lesions were no
longer detectable in the PET component of the examin-
ation. One year after PTX, the patient no longer had
joint pain, remained normocalcemic, was physically
active, and found herself, in retrospect, much stronger
than in many years before.
Discussion
Our patient presented with characteristic symptoms and
signs of HPT. She experienced upper abdominal pain;
polyuria (caused by an acquired resistance to antidiuretic
hormone in the setting of hypercalcemia); polydipsia;
fatigue; and, as we learned later, nephrolithiasis a few
years before. Weight loss and bone pain were initially
misleading and interpreted as red flags of tumor disease.
The occurrence of chondrocalcinosis (occasionally
termed pseudogout, currently termed calcium pyrophos-
phate deposition disease) a few months after PTX is an
entity that has been described in many cases but is not
widely recognized in clinical practice [7, 8].
The laboratory course with postoperative hypocalcae-
mia, disappearance of calcium from urine samples
(calciuria initially below the limit of detection), rise of
AP (but not of phosphate), and an appropriate response
of the remaining parathyroids to serum calcium changes
is typical for HBS, which also supported the diagnosis of
OFC and BTs [1]. A low phosphate level (<0.97 mmol/L)
in conjunction with a low calcium level (<2.1 mmol/L) a
few days after PTX for HPT has been used to define
HBS by some authors [9]. However, HBS could be con-
sidered as mild in our patient because oral treatment
turned out to be sufficient to maintain calcemia and to
prevent tetany, and the patient could be discharged from
the hospital 8 days after PTX.
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Histopathology is commonly considered the gold
standard for medical diagnosis, especially in oncology.
Biopsies are therefore frequently recommended. In
patients with HPT and OFC, typical histopathological
findings of BT biopsies may be hemosiderin deposits,
increased osteoclasts, mononuclear cells, and fibroblasts
[2, 10, 11]. However, as in our patient, biopsies often
show unspecific characteristics and thus remain non-
diagnostic, also owing to the small sample sizes.
In general, BTs present as single or multiple lesions.
Common sites are flat bones, such as the maxillofacial
bone, ribs, clavicle, and pelvic girdle, as well as long
bones, with the diaphysis most commonly affected
(where BTs most likely cause symptoms) [3, 10]. In
keeping with this observation, our patient’s lesions were
situated predominantly in the patellae, pelvic alae, and
scapula. The lesion in the left glenoid demonstrated
subperiosteal bone resorption (Fig. 2e, f ), which is
suggestive of BT. Metastatic involvement is related to
skeletal blood flow and thus may occur predominantly
in the axial skeleton, but it can be scattered throughout
the skeleton [3].
FDG-positive lesions in PET examinations always raise
suspicion of malignancy because cancers are expected to
have high glucose requirements for growth and their
metabolism. However, there remain benign differential
diagnoses; for example, inflammatory cells may show
increased metabolic activity. BTs can present with FDG
avidity in PET despite having benign characteristics [5,
6]. In our patient, there was a picture of multiple, not
uniformly distributed (active and inactive) bone lesions
in 18F-FDG-PET (Fig. 2b). 18F-fluoride-PET (Fig. 2c) is a
very sensitive but unspecific method to detect loci of
increased bone remodeling. Because the patient had
undergone PTX but no chemotherapy before, the
progressive calcification of the bone lesions was more
likely encouraging the diagnosis of BTs rather than
metastases. Of note, blastic bony lesions are considered
typical of metastatic breast cancer; however, lytic metas-
tases do occur. Regarding our experience, we think that
progressive mineralization of formerly lytic bone metas-
tases occurs only as a response to antitumor treatment,
which was not given to our patient. In general, whole-
body bone scintigraphy can evaluate patients for skeletal
metastases, and 18F-FDG-PET seems to exhibit high
specificity and accuracy in detecting bone metastases.
However, there is a limitation of 18F-FDG-PET in
assessing initially sclerotic bone metastases because
some lesions may go undetected, so that 18F-fluoride-
PET might be useful [12].
The key treatment of OFC is PTX. The course of the
disease often takes several months, and the adequate
substitution of calcium up to 1 year after parathyroid
surgery is important to support bone recovery. After 6
months, we performed another radiographic control
because of a persistent concern about missing a con-
comitant malignant disease. Thus, the patient underwent
follow-up 18F-FDG-PET/MRI (Fig. 2d) a few months
after PTX when her bones were no longer too “hungry.”
This scan provided evidence to rule out recurrent breast
cancer. We chose PET/MRI (3.4 mSv) over PET/CT to
keep the patient’s radiation exposure as low as reason-
ably achievable by omitting the additional CT scan.
Conclusions
In our patient’s case, combining information concerning
the clinical presentation and course, the biochemistry la-
boratory examinations, and the imaging (including func-
tional and PET imaging) turned out to be more useful
than biopsies and histopathology. In the overall context,
we finally made the diagnosis of BTs caused by severe
primary HPT.
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